Skip to main content
. 2026 Sep 29;21:623634. doi: 10.2147/CIA.S623634

Table 1.

Baseline

Variable Overall (n=7076) Training (n=4954) Validation (n=2122) P
Sex (Male, n %) 4636 (65.50) 3216 (64.90) 1420 (66.90) 0.111
Weight (kg) 67.80 (10.68) 67.71 (10.75) 68.03 (10.51) 0.237
Age (years) 69.70 (6.40) 69.76 (6.43) 69.57 (6.33) 0.252
CKD (yes, n %) 606 (8.6) 418 (8.4) 188 (8.9) 0.593
Hypertension (yes, n%) 3879 (54.8) 2711 (54.7) 1168 (55.0) 0.825
Diabetes (yes, n %) 1942 (27.4) 1395 (28.2) 547 (25.8) 0.043
CVD (yes, n %) 2928 (41.4) 2064 (41.7) 864 (40.7) 0.475
COPD (yes, n %) 551 (7.8) 392 (7.9) 159 (7.5) 0.579
Arrhythmia (yes, n %) 1712 (24.2) 1216 (24.5) 496 (23.4) 0.306
Stroke (yes, n %) 1088 (15.4) 741 (15.0) 347 (16.4) 0.146
VHD (yes, n %) 1541 (21.8) 1090 (22.0) 451 (21.3) 0.504
Diuretic yes, (n %) 4381 (61.9) 3094 (62.5) 1287 (60.7) 0.16
Vasoactive drugs (yes, n %) 2247 (31.8) 1592 (32.1) 655 (30.9) 0.307
ACEIs/ARBs (yes, n %) 3676 (52.0) 2526 (51.0) 1150 (54.2) 0.014
Anticoagulants (yes, n %) 2941 (41.6) 2066 (41.7) 875 (41.2) 0.734
Antiplatelet drugs (yes, n %) 4472 (63.2) 3106 (62.7) 1366 (64.4) 0.189
Urine protein (yes, n%) 1136 (16.1) 805 (16.2) 331 (15.6) 0.517
LVEF (%) 0.52 ± 0.12 0.52 ± 0.12 0.52 ± 0.12 0.609
WBC (×109/L) 7.55 ± 3.03 7.57 ± 3.08 7.52 ± 2.92 0.51
RBC (×1012/L) 4.27 ± 0.66 4.27 ± 0.67 4.28 ± 0.65 0.751
Hb (g/L) 131.86 ± 22.10 131.78 ± 22.43 132.03 ± 21.31 0.665
Plt (×109/L) 197.41 ± 55.71 196.71 ± 55.98 199.06 ± 55.07 0.103
CRP (mg/L) 4.35 (1.40, 20.40) 4.40 (1.40, 20.48) 4.30 (1.37, 20.37) 0.625
Total bilirubin (μmol/L) 9.40 (5.90, 13.90) 9.50 (5.90, 13.90) 9.40 (5.90, 13.80) 0.554
ALT (U/L) 19.48 (15.00, 27.36) 19.61 (15.00, 27.20) 19.20 (15.00, 27.64) 0.964
AST (U/L) 20.87 (14.07, 33.95) 20.77 (14.01, 34.12) 21.00 (14.29, 33.61) 0.643
AKP (U/L) 65.32 ± 25.69 64.99 ± 25.73 66.08 ± 25.58 0.104
Alb (g/L) 36.68 ± 4.96 36.72 ± 5.00 36.59 ± 4.85 0.337
BUN (mmol/L) 6.95 (5.55, 9.03) 6.98 (5.57, 9.05) 6.88 (5.52, 8.95) 0.524
SCr (μmol/L) 77.90 (63.90, 88.40) 77.89 (63.60, 88.20) 78.00 (64.70, 88.68) 0.219
Cysc (mg/L) 1.04 (0.87, 1.33) 1.04 (0.87, 1.34) 1.05 (0.87, 1.32) 0.473
Uric acid (μmol/L) 368.00 (294.00, 456.00) 369.00 (293.00, 453.75) 366.00 (297.00, 462.00) 0.388
Glu (mmol/L) 7.15 ± 3.12 7.16 ± 3.10 7.13 ± 3.15 0.742
CtnT (ng/L) 0.88 (0.01, 24.00) 1.00 (0.01, 24.00) 0.43 (0.01, 24.00) 0.561
NT-proBNP (pg/mL) 2098.00 (656.08, 3832.28) 2075.50 (664.52, 3832.28) 2175.50 (641.60, 3832.28) 0.578
T chol (mmol/L) 3.85 (3.18, 4.62) 3.85 (3.17, 4.62) 3.84 (3.19, 4.63) 0.495
TGs (mmol/L) 1.22 (0.90, 1.69) 1.23 (0.91, 1.69) 1.20 (0.90, 1.70) 0.582
HDL (mmol/L) 1.05 (0.88, 1.25) 1.05 (0.88, 1.25) 1.05 (0.88, 1.26) 0.504
LDL (mmol/L) 2.18 (1.68, 2.79) 2.18 (1.68, 2.79) 2.17 (1.70, 2.79) 0.892
D dimer (mg/L) 0.45 (0.26, 1.13) 0.45 (0.26, 1.16) 0.44 (0.27, 1.10) 0.301
β-blocker (yes, n %) 4506 (63.7) 3174 (64.1) 1332 (62.8) 0.311
CCB (yes, n %) 1760 (24.9) 1243 (25.1) 517 (24.4) 0.536
Cardiac function grade, n (%) 2.57 (0.91) 2.57 (0.91) 2.57 (0.90) 0.93
I 753 (10.6) 542 (10.9) 211 (9.9) 0.385
II 2843 (40.2) 1963 (39.6) 880 (41.5)
III 2199 (31.1) 1553 (31.3) 646 (30.4)
IV 1281 (18.1) 896 (18.1) 385 (18.1)

Notes: Data are presented as n (%), mean ± SD, or median (IQR), as appropriate. The numbers in each cell represent subgroup counts within the training or validation set, not the total sample size of that cohort.

Abbreviations: AKI, acute kidney injury; ACEIs/ARBs, angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers; LVEF, left ventricular ejection fraction; WBC, white blood cell count; RBC, red blood cell count; Hb, haemoglobin; Plt, platelet count; CRP, C-reactive protein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AKP, alkaline phosphatase; Alb, albumin; BUN, blood urea nitrogen; SCr, serum creatinine; Cysc, cystatin C; Glu, glucose; CtnT, cardiac troponin T; NT-proBNP, N-terminal pro-B-type natriuretic peptide; T chol, total cholesterol; TG, triglycerides; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol.